Barbiturate anesthesia in the treatment of status epilepticus: clinical experience with 14 patients.
We report our experience using barbiturate anesthesia for the treatment of refractory status epilepticus. Following a retrospective review of eight patients treated with a variety of barbiturates and dosing regimens, we established a specific protocol employing pentobarbital and evaluated it prospectively in six patients. Among the 14 patients, intravenous barbiturates, when administered with a loading dose followed by continuous infusion, were uniformly effective in aborting seizures and producing a burst-suppression EEG pattern. Other than the pupillary light reflex, most patients lost all brainstem reflexes and motor responses during therapy. Barbiturate-induced hypotension was observed in 9 of the 14 patients, and required treatment with pressors in seven cases. Three patients died early as a consequence of their underlying illness, while three others died late for reasons unrelated to the status itself or to anticonvulsant therapy. The time to recovery of function following anesthesia varied highly, spanning hours to days for return of motor function and days to weeks for cognition. Of the eight survivors, four were left with mild cognitive deficits, one returned to his baseline dementia, and three had residual encephalopathies (severe in two). We conclude that barbiturate anesthesia is an extremely effective therapy for refractory seizures. However, its use necessitates recognition of untoward cardiovascular responses and prolonged intensive care.
Lowenstein
D H
DH
Department of Neurology, School of Medicine, University of California, San Francisco 94143.
Aminoff
M J
MJ
Simon
R P
RP
D000758:Anesthesia; D002319:Cardiovascular System / Q000503:physiopathology; D002986:Clinical Trials as Topic; D006801:Humans; D007262:Infusions, Intravenous; D009420:Nervous System / Q000503:physiopathology; D010424:Pentobarbital / Q000097:blood; D011446:Prospective Studies; D013226:Status Epilepticus / Q000503:physiopathology / Q000628:therapy*
D010424:Pentobarbital